Plain-English translation of NCT04752826 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This trial is testing a new medication called , which is an antibody designed to help your immune system fight cancer. You would receive either the medication alone, or combined with pembrolizumab (an existing immunotherapy drug), or combined with both pembrolizumab and paclitaxel (a chemotherapy). The study starts with small groups to find the safest doses, then expands to larger groups to see how well the treatment works.
Many people with advanced cancer stop responding to standard treatments, leaving them with few options. This trial is exploring whether this medication can boost the body's own immune defenses to fight cancer more effectively, either as a standalone treatment or to enhance other existing therapies.
You likely qualify if…
You likely don't qualify if…
You would receive the medication intravenously (by IV infusion) at regular visits to the study center. The first phase involves small groups receiving increasing doses to determine safety; the second phase involves larger groups receiving the optimal dose to assess effectiveness. Throughout the trial, you would have blood tests, imaging scans, and possibly biopsies to monitor how the treatment is working and any side effects. The study timeline extends beyond the initial treatment period to track how long responses last.
AI-generated summary from trial data · Sep 19, 2026 · Not medical advice
United States
Denmark